Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational Results available

A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients

NCT02086682
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Dialysis, Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
Marie Hogan
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational Results available

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions

NCT01917682
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
CorPath-assisted Percutaneous Coronary Intervention
Procedure
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
San Diego, California • Glenwood Springs, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

NCT00509223
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Positive Airway Pressure therapy, Lifestyle counseling
Device · Behavioral
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo tablets, Riluzole
Drug · Other
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones

NCT00381849
View directory record Official record
Conditions
Cystinuria, Nephrolithiasis, Calcium Oxalate
Interventions
Cystone, Sugar Pill (Placebo)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378
View directory record Official record
Conditions
Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions
TRx0237, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational

Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage in Biliary Obstruction

NCT04857424
View directory record Official record
Conditions
Biliary Obstruction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting No phase listed Observational

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT04574635
View directory record Official record
Conditions
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma, Stage I Cervical Cancer FIGO 2018, Stage IA Cervical Cancer FIGO 2018, Stage IA1 Cervical Cancer FIGO 2018, Stage IA2 Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IV Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IVB Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

NCT04200378
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational

Mechanisms in Heart Failure With Normal EF

NCT00587808
View directory record Official record
Conditions
Heart Failure
Interventions
RHC with VO2 consumption
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck

NCT00474825
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Cancer of the Head and Neck
Interventions
Hyperbaric Oxygen Therapy, Hyperbaric oxygen
Drug
Lead sponsor
National Baromedical Services
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Completed No phase listed Observational

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

NCT02503696
View directory record Official record
Conditions
Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years to 84 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
27
States / cities
Dothan, Alabama • La Jolla, California • Mission Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT03516617
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 30, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 4:13 PM EDT